Rénald Gilbert

Dr. Rénald Gilbert

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in BMC Biotechnology
Verified
Journal Article
Open access
PDF file
ACAntoine W Caron
Antoine W Caron
CNClaire Nicolas
Claire Nicolas
BGBruno Gaillet
Bruno Gaillet
IBIsmaïla Ba
Ismaïla Ba
MPMaxime Pinard
Maxime Pinard
RGRénald Gilbert
Rénald Gilbert
Despite the powerful impact in recent years of gene expression markers like the green fluorescent protein (GFP) to link the expression of recombinant protein for selection of high producers, there is a strong incentive to develop rapid and efficient methods for isolating mammalian cell clones secreting high levels of marker-free recombinant proteins. Recently, a method combining cell colony growth in methylcellulose-based medium with detection by a fluorescently labeled secondary antibody or antigen has shown promise for the selection of Chinese Hamster Ovary (CHO) cell lines secreting recombinant antibodies. Here we report an extension of this method referred to as fluorescent labeling in semi-solid medium (FLSSM) to detect recombinant proteins significantly smaller than antibodies, such as IGF-E5, a 25 kDa insulin-like growth factor derivative. CHO cell clones, expressing 300 μg/ml IGF-E5 in batch culture, were isolated more easily and quickly compared to the classic limiting dilution method. The intensity of the detected fluorescent signal was found to be proportional to the amount of IGF-E5 secreted, thus allowing the highest producers in the population to be identified and picked. CHO clones producing up to 9.5 μg/ml of Tissue-Plasminogen Activator (tPA, 67 kDa) were also generated using FLSSM. In addition, IGF-E5 high-producers were isolated from 293SF transfectants, showing that cell selection in semi-solid medium is not limited to CHO and lymphoid cells. The best positive clones were collected with a micromanipulator as well as with an automated colony picker, thus demonstrating the method's high throughput potential. FLSSM allows rapid visualization of the high secretors from transfected pools prior to picking, thus eliminating the tedious task of screening a high number of cell isolates. Because of its rapidity and its simplicity, FLSSM is a versatile method for the screening of high producers for research and industry.

1 January 2019 in Journal of Biotechnology
Verified
Journal Article
Closed access
SESeyyed Mehdy Elahi
Seyyed Mehdy Elahi
CSChun Fang Shen
Chun Fang Shen
RGRénald Gilbert
Rénald Gilbert

15 July 2023 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
LJLovro Jalšić
Lovro Jalšić
VLViktoria Lytvyn
Viktoria Lytvyn
SESeyyed Mehdy Elahi
Seyyed Mehdy Elahi
SHSabahudin Hrapovic
Sabahudin Hrapovic
NNNasha Nassoury
Nasha Nassoury
RGRénald Gilbert
Rénald Gilbert
Packaging or producer cell lines for scalable recombinant adeno-associated virus (rAAV) production have been notoriously difficult to create due in part to the cytostatic nature of the Rep proteins required for AAV production. The most difficult challenge being creating AAV packaging cell lines using HEK293 parental cells, currently the best mammalian platform for rAAV production due to the constitutive expression of E1A in HEK293 cells, a key REP transcription activator. Using suspension and serum-free media adapted HEK293SF carrying a gene expression regulation system induced by addition of cumate and coumermycin, we were able to create REP-expressing AAV packaging cells. This was achieved by carefully choosing two of the AAV Rep proteins (Rep 40 and 68), using two inducible promoters with different expression levels and integrating into the cells through lentiviral vector transduction. Three of our best clones produced rAAV titers comparable to titers obtained by standard triple plasmid transfection of their parental cells. These clones were stable for up to 7 weeks under continuous cultures condition. rAAV production from one clone was also validated at scale of 1 L in a wave bioreactor using serum-free suspension culture.

1 November 2014 in Journal of Virological Methods
Verified
Journal Article
Closed access
RGRénald Gilbert
Rénald Gilbert
CGClaire Guilbault
Claire Guilbault
DGDavid Gagnon
David Gagnon
ABAlice Bernier
Alice Bernier
LBLucie Bourget
Lucie Bourget
BMBernard Massie
Bernard Massie

1 December 2023 in Vaccine
Verified
Journal Article
Closed access
AGAnahita Bakhshizadeh Gashti
Anahita Bakhshizadeh Gashti
GAGerard Agbayani
Gerard Agbayani
Sabo HrapovicSabo Hrapovic
Sabo Hrapovic
NNNasha Nassoury
Nasha Nassoury
NCNathalie Coulombe
Nathalie Coulombe
PCParminder Singh Chahal
Parminder Singh Chahal

1 September 2023 in Human Gene Therapy
Verified
Journal Article
Closed access
NMNeel Mehta
Neel Mehta
RGRénald Gilbert
Rénald Gilbert
PCParminder S. Chahal
Parminder S. Chahal
MMMaria J Moreno
Maria J Moreno
NNNasha Nassoury
Nasha Nassoury
MHMichael R. Hayden
Michael R. Hayden
Lipoprotein lipase deficiency (LPLD) results from mutations within the lipoprotein lipase (LPL) gene that lead to a complete lack of catalytically active LPL protein. Glybera was one of the first adeno-associated virus (AAV) gene replacement therapy to receive European Medicines Agency regulatory approval for the treatment of LPLD. However, Glybera is no longer marketed potentially due to a combination of economical, manufacturing and vector related issues. The aim of this study was to develop a more efficacious AAV gene therapy vector for LPLD. Following preclinical biodistribution, efficacy and non-GLP toxicity studies with novel AAV1 and AAV8-based vectors in mice, we identified AAV8 pVR59. AAV8 pVR59 delivered a codon optimized, human gain-of-function hLPLS447X transgene driven by a CAG promoter in an AAV8 capsid. AAV8 pVR59 was significantly more efficacious, at 10- to 100-fold lower doses, compared to an AAV1 vector based on Glybera, when delivered intramuscularly or intravenously, respectively, in mice with LPLD. Efficient gene transfer was observed within the injected skeletal muscle and liver following delivery of AAV8 pVR59, with long-term correction of LPLD phenotypes, including normalization of plasma triglycerides and lipid tolerance, for up to 6 months post-treatment. While intramuscular delivery of AAV8 pVR59 was well tolerated, intravenous administration augmented liver pathology. These results highlight the feasibility of developing a superior AAV vector for the treatment of LPLD and provide critical insight for initiating studies in larger animal models. The identification of an AAV gene therapy vector that is more efficacious at lower doses, when paired with recent advances in production and manufacturing technologies, will ultimately translate to increased safety and accessibility for patients.